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Abstract
Objective The objective of the study is to evaluate the effect
of gastric banding, gastric bypass and sleeve gastrectomy on
medium to long-term diabetes control in obese participants
with type 2 diabetes mellitus.
Research Design and Methods Matched cohort study using
primary care electronic health records from the UK Clinical
Practice Research Datalink. Obese participants with type 2
diabetes who received bariatric surgery from 2002 to 2014
were compared with matched control participants who did
not receive BS. Remission was defined for each year of
follow-up as HbA1c <6.5 % and no antidiabetic drugs
prescribed.
Results There were 826 obese participants with T2DM who
received bariatric surgery including adjustable gastric banding
(LAGB) 220; gastric bypass (GBP) 449; or sleeve gastrecto-
my (SG) 153; with four procedures undefined. Mean HbA1c
declined from 8.0 % before BS to 6.5 % in the second post-
operative year; proportion with HbA1c <6.5 % (<48 mmol/
mol) increased from 17 to 47 %. The proportion of patients in
remission was 30% in the second year, being 20% for LAGB,
34 % for GBP and 38 % for SG. The adjusted relative rate of
remission over the first six postoperative years was 5.97 (4.86
to 7.33, P<0.001) overall; for LAGB 3.32 (2.27 to 4.86);
GBP 7.16 (5.64 to 9.08); and SG 6.82 (5.05 to 9.19). Rates
of remission were maintained into the sixth year of follow-up.
Conclusions Remission of diabetes may continue for up to
6 years after bariatric surgical procedures. Diabetes outcomes
are generally more favourable after gastric bypass or sleeve
gastrectomy than LAGB.
Keywords Bariatric surgery . Type 2 diabetesmellitus .
Primary care . Electronic health records . Antidiabetes drugs
Abbreviations
GBP Gastric bypass
LAGB Laparoscopic adjustable gastric banding
SG Sleeve gastrectomy
T2DM Type 2 diabetes mellitus
Introduction
The potential role of bariatric surgery in the prevention [1, 2] and
treatment [3] of diabetes in individuals with severe obesity is
increasingly recognised [4]. A systematic review found that use
of bariatric surgery in obese patients with type 2 diabetes was
associated with remission of diabetes in approximately 70 % of
patients over the first 2 years following surgery [5]. Most
randomised trials have evaluated outcomes for small samples
of patients, with outcomes reported more than 2 years following
surgery only for a few patients [6, 7]. There are similarly few
non-randomised studies that have reported on outcomes of dia-
betic patients more than 2 years after bariatric surgery [8]. The
largest and longest-running study, the Swedish obese subjects
(SOS) study, reported rates of remission of 38% at 10 years and
30 % at 15 years follow-up, with fewer microvascular and
macrovascular complications of diabetes in patients receiving
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surgery [9]. Although this study does provide important infor-
mation, it should be noted that the majority of participants in the
SOS cohort received the vertical band gastroplasty procedure—
which is no longer widely utilised. There is a dearth of informa-
tion on the long-term outcome data for currently used bariatric
surgical procedures, including gastric banding and gastric by-
pass procedures, with data being especially limited for sleeve
gastrectomy. In addition, most studies have been carried out in
research centres and there are few pragmatic studies of the out-
comes of patients treated in usual clinical practice settings.
We have utilised primary care electronic health records from a
large database of UK family practices in order to perform a
population-based comparison study of patients receiving current-
ly used bariatric surgical procedures withmatched obese subjects
who did not undergo surgery. In a previous report, we evaluated
the effect of bariatric surgery in the prevention of diabetes in
obese subjects [1, 10]. In the present study, we aimed to compare
the effect of the three different bariatric surgical procedures, gas-
tric banding, gastric bypass and sleeve gastrectomy, on diabetes
remission, and to evaluate the extent to which rates of remission
were maintained over a maximum of 6 years of follow-up.
Methods
Data Source
Participants were sampled from the UK Clinical Practice
Research Datalink (CPRD). The CPRD is a continuously-
updated collection of primary care electronic health records
from 1990 to the present. The CPRD presently draws data
from approximately 680 general medical practices across the
UK with a registered population of more than 5 million that is
socio-demographically representative of the UK general pop-
ulation [11]. Data collected into CPRD include all consulta-
tions, referrals and hospital letters, drug prescriptions and
medical tests for registered patients. Research quality data in
CPRD conform to defined standards for research quality and
the validity of CPRD clinical diagnoses has been documented
[12]. Data were extracted from theMay 2013 release of CPRD
with potential follow-up to 30th April 2014.
Participants
For the present study, participants aged 20 years or over were
selected if they had a diagnosis of bariatric surgery recorded
more than 12 months after the start of their CPRD record, had a
recorded body mass index (BMI) record ≥30 Kg/m2 and were
diagnosed with type 2 diabetes mellitus before the date of sur-
gery. A minimum BMI value of 30 Kg/m2 was employed to
ensure that all participants were obese but some BMI records
dated from several years before operation and might not reflect
pre-operative BMI. Baseline BMI values were recorded a
median of 1.6 years (interquartile range 0.6 to 5.4 years) before
surgery. Bariatric surgery procedures were identified using
medical codes for laparoscopic adjustable gastric banding
(LAGB), gastric bypass (GBP) or sleeve gastrectomy (SG). A
diagnosis of type 2 diabetes was taken as the earlier of a med-
ical diagnosis of diabetes, a prescription for antidiabetes med-
icines, or an HbA1c value >6.5 % (48 mmol/mol). Participants
who were diagnosed with polycystic ovary syndrome and pre-
scribed diabetes medicines, but not diagnosed with diabetes
were excluded. Participants who were ever diagnosed with ges-
tational diabetes were also excluded from these analyses.
Control participants were selected who never had bariatric
surgery recorded, but were obese and had type 2 diabetes
mellitus diagnosed before the index date. As the distribution
of BMI differed greatly betweenBS cases and the CPRD obese
population, control participants were individually matched
with cases using nearest neighbour matching on BMI, age,
sex and index year. The index date for controls was the date
of the first BMI record on which they entered their highest
recorded BMI category. Participant records ended if they ter-
minated their registration with a CPRD general practice; if their
general practice ended participation in CPRD; if the latest
data collection date was reached; or if the patient died.
There were 4793 obese participants with bariatric surgery
recorded, 1324 were excluded because the index code was
within 12 months of the start of the record, 14 were excluded
with age less than 20 years, 401 were excluded because their
BMI was less than 30 or no values were recorded before
surgery, 2176 were excluded as non-diabetic, leaving 878
obese participants with type 2 diabetes of whom 52 were
excluded with gestational diabetes ever recorded. There were
then 826 obese participants with type 2 diabetes diagnosed
before surgery who were matched with 826 obese diabetic
controls who did not receive surgery.
Participants were registered at 360 general practices, of
which 92 % continued their participation in CPRD until
2013 or later; there were 69 participants that ended their reg-
istration with a CPRD practice before 2013. There were 20
participants who died during the period of follow-up.
Main Measures and Analysis
HbA1c records and prescriptions for oral hypoglycaemic
drugs and insulin were evaluated for BS cases and controls.
The person time for each participant was divided into study
years from 3 years before the procedure to 6 years after the
procedure. This allowed us to conduct an interrupted time-
series analysis. Follow-up was censored at 6 years because
few cases remained under follow-up for sleeve gastrectomy
and gastric bypass. The highest HbA1c value and the total
number of diabetes prescriptions were evaluated in each study
year. For each year of follow-up, participants were classified
as being in remission if the maximum HbA1c value recorded
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in year was <6.5 % and there were no diabetes prescriptions
issued in the year. Relative rates were estimated for each year
following the BS procedure by using a Poisson model with
person time as the exposure. A model was fitted to evaluate
the effect of group (BS or control) and time after surgery,
included as indicator variables for each postoperative year
(13). Confounders included age, gender, BMI, quartile of di-
abetes duration before surgery, whether coronary heart disease
(CHD), stroke or depression were diagnosed before the index
date, whether blood pressure (BP) was ≥140/90 mmHg or
serum total cholesterol ≥5 mmol/L, and whether antihyperten-
sive drugs and lipid-lowering drugs were prescribed before the
index date, and current smoking recorded before the index
date.
Results
Baseline characteristics of the bariatric surgery participants
and controls are shown in Table 1. Bariatric surgery partici-
pants and controls were generally similar with respect to age,
gender and index year but the baseline BMI was higher in the
BS participants. BS participants also had longer duration of
diabetes with a median duration of 5.5 years since diagnosis,
compared with 3.1 years for controls. BS participants were
more likely to be treated with statins and antihypertensive
drugs, with lower blood pressure and cholesterol values, and
were less likely to be current smokers.
There were 220 (27 %) BS patients who received LAGB,
449 (54 %) received gastric bypass (GBP) procedures, 153
(19 %) received sleeve gastrectomy (SG). The type of proce-
dure was undefined for four participants with more than one
operation type coded on the index date. LAGB procedures
were used in clinical practice at an earlier time having a me-
dian index year of 2009, compared with 2011 for gastric by-
pass or sleeve gastrectomy.
Tables 2 and 3 show data for the number of participants
contributing person time to the analysis, from 3 years before to
6 years after the BS procedure. The proportion of participants
contributing person time in each postoperative year declined
rapidly because more than 50% of procedures were within the
last 4 years and only 13 % of participants contributed person
time in the sixth year of follow-up. Participants receiving
LAGB contributed a higher proportion of person time at long
follow-up. The proportion of participants with HbA1c values
recorded generally ranged between 60 and 80% (Tables 2 and
3). At the time of surgery, slightly more BS patients had
HbA1c values recorded, but at longer durations of follow-
up, HbA1c recording was more complete in controls than
BS patients.
Trends in meanHbA1c and proportion with HbA1c <6.5%
(<48 mmol/mol) are shown by year following surgery in
Fig. 1. The mean HbA1c value in the year before the
index date was 8.0 % (64 mmol/mol) in BS cases and
8.3 % (67 mmol/mol) in controls. The mean HbA1c
value in BS cases declined to 6.8 % (51 mmol/mol),
6.5 % (48 mmol/mol) and 6.8 % (51 mmol/mol) in
the first 3 years following surgery, but remained un-
changed at 8.1 % (65 mmol/mol), 8.2 % (66 mmol/
mol) and 8.2 % (66 mmol/mol), respectively in controls.
The proportion of BS cases with HbA1c values <6.5 %
(<48 mmol/mol) was 17 % before operation, increasing
to 44, 47 and 39 % in the first three postoperative
years. No consistent trend in the proportion of controls
with HbA1c <6.5 % (<48 mmol/mol) was observed.
Trends in the proportion of participants without
antidiabetes drug prescriptions and the mean number
of drug prescriptions per participant year are also shown
for BS cases and controls in Fig. 1. The proportion of
BS cases without antidiabetic drugs or insulin prescrip-
tions increased from 15 % before operation to 41, 53
and 55 % in the first 3 years after surgery, while the
opposite trend was observed in controls.
Table 1 Baseline characteristics
of bariatric surgery participants
and controls. Figures are
frequencies (column percent)
except where indicated
BS participants Control participants P value
Number 826 826
Female 542 (66) 524 (63) 0.390
Age (years, mean SD) 50.0 (9.6) 49.1 (13.8) 0.118
Body mass index (Kg/m2) 46.7 (8.3) 44.2 (6.5) <0.001
Index year (median, interquartile range) 2011 (2009 to 2012) 2011 (2010 to 2012) 0.495
Diabetes duration (years, median, interquartile
range)
5.5 (2.4 to 9.3) 3.1 (0.3 to 7.1) <0.001
Antihypertensive therapy 632 (77) 517 (63) <0.001
Blood pressure >140/90 mmHg 247 (30) 287 (35) 0.027
Statin therapy 579 (70) 451 (55) <0.001
Total cholesterol >5 mmol/L 217 (26) 257 (31) <0.001
Current smoking 117 (14) 189 (23) <0.001
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The proportion of BS cases in remission was 5 %
before operation, increasing to 21, 30 and 25 % in the
first 3 years after surgery (Table 2), while the propor-
tion of controls in remission tended to remain constant
over time. In the first year after surgery, the proportion
of participants in remission was lower for LAGB pa-
tients (7 %, 95 % confidence interval 4 to 11 %) than
for patients receiving either gastric bypass (25 %, 21 to
29 %) or sleeve gastrectomy (31 %, 24 to 39 %)
(Table 3). When remission was evaluated only including
participants with HbA1c values recorded in a given
year, then the proportion of participants in remission
for the first and subsequent years following the proce-
dure was 27, 41, 39, 33, 35 and 26 %; the equivalent
figures for controls were 6, 5, 7, 5, 7 and 7 %. The
proportion of participants with either HbA1c <6.5 %, or
not taking medications, was higher than the proportion
of participants in remission, which required both criteria
to be met. Of the 744 person years in remission among
bariatric surgery cases, 175 (24 %) were not in com-
plete remission (HbA1c <6.0 %). The proportion of BS
participants in complete remission in the second year
after the procedure was 26 %.
Multivariable adjusted analyses were conducted using par-
ticipant years as observations (Table 2 and 3). The adjusted
relative rate of diabetes remission across all types of bariatric
surgery, relative to person time without surgery, was 4.66
(95 % confidence interval 3.80 to 5.73) in the first year after
surgery increasing to 7.16 (5.79 to 8.86) in the second year. By
the sixth year of follow-up, the adjusted relative rate was 5.90
(3.72 to 9.34). In participants receiving LAGB, compared
with all controls, the adjusted relative rate of diabetes remis-
sion was not elevated in the first postoperative year but in-
creased to 4.16 (2.84 to 6.11) in the second postoperative year.
The rate of remission remained elevated for the sixth year of
follow-up (3.19, 1.70 to 5.97). For either gastric bypass or
sleeve gastrectomy, the rate of diabetes remission was in-
creased in the first year following the procedure (GBP 5.83,
4.55 to 7.48; SG 6.21, 4.59 to 8.41) and remained elevated
until the end of the sixth year of follow-up (GBP 11.7, 5.15 to
26.6; SG 8.53, 3.75 to 19.4). For these procedures, adjusted
rate ratios were higher than for LAGB, though confidence
intervals overlapped. There were small numbers of observa-
tions for the later years of follow-up for gastric bypass and
sleeve gastrectomy. Associations of confounders with remis-
sion were generally of small magnitude except for a graded
association of duration of diabetes, with the highest quartile of
diabetes duration (diabetes diagnosed more than 8.6 years be-
fore surgery) being associated with reduced relative risk of
remission of 0.23 (95 % confidence interval 0.16 to 0.33,
P<0.001).
Table 4 presents adjusted rate ratios for diabetes remission
for combining the 6 years of follow-up. The adjusted relative
rate of diabetes remission after bariatric surgery compared
with controls was 5.97 (95 % confidence interval 4.86 to
7.33, P<0.001). The three types of bariatric surgery each
resulted in a significantly higher rates of diabetes remission
compared with controls (all P < 0.001). However, the
rate of remission was lower after LAGB 3.32 (2.27 to
4.86), compared with gastric bypass (7.16, 5.64 to 9.08)
or sleeve gastrectomy (6.82, 5.05 to 9.19). The relative
rate of diabetes remission was slightly higher in men
compared to women. The relative rate of diabetes remis-
sion increased with increasing BMI category, being 6.74
(5.29 to 8.58) with BMI ≥40 Kg/m2 but 4.23 (95 % CI
1.98 to 9.03) at BMI ≥30 Kg/m2. The relative rate of
diabetes remission was highest in participants aged 35
to 54 years.
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Discussion
Our study demonstrates that bariatric surgery was associated
with a sixfold increase in diabetes remission compared with
no bariatric surgery and that patients receiving either gastric
bypass or sleeve gastrectomy procedures, rather than gastric
banding, showed earlier onset and higher rates of diabetes
remission. Changes in mean HbA1c in our study were similar
to those reported in previous studies [13]; rates of diabetes
remission after surgery in the present study were significantly
lower than those reported in published reviews [6, 14, 15] and
in UK National Bariatric Surgery Registry (NBSR) data,
which reported 80 % of patients to be in remission 3 years
post-surgery [16]. A retrospective cohort study by Arterburn
et al. [17] found partial diabetes remission rates of 47, 73 and
77 % at 1, 3 and 5 years after gastric bypass surgery. The
reasons for the differences in observed remission rates are
not clear, although patients in our study had a slightly longer
history of diabetes, which Arterburn et al. found to reduce
likelihood of remission. The proportion of patients in remis-
sion declined over time following surgery and there was bio-
chemical evidence that individual patients showed relapse of
diabetes after a period of remission. It should be noted that we
used a stringent definition of remission that required a normal
HbA1c value to be recorded in each year and patients who had
missing values for HbA1c were assumed not to be in remis-
sion. A recent paper using CPRD data found overall 28 %
diabetes remission, based on ‘remission’ recorded by family
physicians [18]. When remission rates were estimated includ-
ing only participants with HbA1c values recorded in year, the
proportion of participants in remission was higher. Missing
HbA1c values may have been related to diabetes control,
possibly with less frequent recording in patients who are in
remission or have good control. In clinical practice, some
patients may be continued on metformin therapy even in the
setting of apparent biochemical remission and underestima-
tion of remission may also occur if patients receive repeat
prescriptions for medicines they no longer require.
Conversely, relapse after previous remission may not be de-
tected if blood glucose control is not evaluated. Even allowing
for these limitations, this pragmatic study raises questions
concerning whether the results achieved in routine practice
may be as favourable as those reported from research studies.
Previous studies suggest that gastric bypass is more effec-
tive for the treatment of diabetes than LAGB [5, 14]. This
finding is replicated in our study, and in addition, we found
that sleeve gastrectomy was superior to gastric banding and
similarly as effective as gastric bypass in leading to diabetes
remission. This result contradicts a randomised controlled trial
in 60 patients by Lee et al., who demonstrated superior
glycaemic control in diabetic patients undergoing mini-
gastric bypass as opposed to sleeve gastrectomy [19].
Although the majority of sleeve gastrectomies occurred in
the later part of the study and pragmatic observational studies
are more susceptible to bias than results from randomised
trials, our results do suggest that sleeve gastrectomy may be
as effective as gastric bypass for diabetes remission. Previous
studies have shown higher diabetes remission rates in patients
with greater post-surgery weight loss [5]. Unfortunately, we
were unable to assess this recording of weight over time in
primary care is very limited, even in this high-interest sub-
group of patients. Our results offer some suggestion that the
effect of bariatric surgery may decline over time; however, we
accept the low overall follow-up rate and the fact that the
Table 4 Association of bariatric surgery with diabetes remission by age group, gender, BMI category and procedure type
Adjusteda rate ratio (95 % confidence interval) P value
All BS procedures 5.97 (4.86 to 7.33) <0.001
Type of procedureb Laparoscopic gastric banding 3.32 (2.27 to 4.86) <0.001
Gastric bypass 7.16 (5.64 to 9.08) <0.001
Sleeve gastrectomy 6.82 (5.05 to 9.19) <0.001
Sex Men 7.70 (5.26 to 11.3) <0.001
Women 5.32 (4.16 to 6.81) <0.001
Baseline BMI category (Kg/m2) 30–34.9 4.23 (1.98 to 9.03) <0.001
35–39.9 3.59 (2.16 to 5.97) <0.001
≥40 6.74 (5.29 to 8.58) <0.001
Age group (years) 20 to 34 5.38 (2.81 to 10.3) <0.001
35 to 54 6.69 (5.05 to 8.86) <0.001
≥55 5.52 (3.91 to 7.80) <0.001
BMI body mass index, BP blood pressure, BS bariatric surgery, CHD coronary heart disease
a Adjusted for age, gender, BMI, diabetes duration quartile, prevalent CHD, stroke, depression, smoking status, elevated total cholesterol, high blood
pressure, use of antihypertensive drugs and statins, and year of procedure
b Three cases with more than one procedure coded on index date were excluded
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majority of long-term follow-up data is from LABG does limit
the conclusions which can be drawn.
This study has several limitations. The available duration
of follow-up was generally shorter for gastric bypass and
sleeve gastrectomy procedures than for patients who received
LAGB as a consequence of the changes in popularity of these
procedures over time. In addition, control patients were not
treated using a standardised weight loss programme, and it is
possible that diabetes management in the two groups also
differed. Surgery patients may have had better access to spe-
cialist diabetes care in the run-up to their surgery. While cases
and controls were matched, there were residual differences for
some variables including duration of diabetes, which was lon-
ger in the surgical group. However, our analyses were adjust-
ed for potential confounders. Perhaps, most importantly, there
was a persistent issue of missing and inconsistently recorded
data as detailed previously. The analyses were conducted on
an ‘intention to treat’ basis, and though small numbers of
participants may have had further bariatric procedures, these
were not excluded.
In conclusion, this is one of the largest prospective prag-
matic studies on the impact of bariatric surgery on diabetes
outcomes and demonstrates that bariatric surgery (and in par-
ticular gastric bypass and sleeve gastrectomy) may facilitate
diabetes control in obese patients treated in routine primary
care settings. The three most commonly used surgical tech-
niques were associated with increased rates of remission, im-
proved blood glucose control and reduced use of antidiabetes
medications for type 2 diabetes mellitus over a maximum of 6-
year follow-up period. Rates of remission tended to decline
over time and there was biochemical evidence of relapse in
some participants. There remains a clear need for longer-term
follow-up studies to assess the clinical- and cost-effectiveness
of bariatric surgery on diabetes outcomes, including assess-
ments of adverse events and safety.
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